Pharmacologically active polymers, 6. Sulfadiazine and boron derivatives as potential carriers for polymers into cancer tissue

Bartulin, J.; Przybylski, Michael; Ringsdorf, Helmut; Ritter, Helmut

doi:10.1002/macp.1974.021750327

Cited by 30 publications

(8 citation statements)

References 4 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…79,84,86,87,219,322,380 It also enables the localization of a high concentration of drugs at a desired site of the body. Polymer-drug conjugates as prodrugs require the use of uniform polymers to be able to obtain a consistent in ViVo profile with an identifiable structure-activity correlation.…”

Section: Soluble Polymer-drug Conjugatesmentioning

confidence: 99%

Bioapplications of RAFT Polymerization

et al. 2009

View full text Add to dashboard Cite

His Ph.D. was in collaboration with Solvay-Solexis and devoted to the synthesis of new graft copolymers using grafting "to". In 2005, he undertook a postdoctorate position with Dupont Performance and Elastomers (Willmington, United States) and Dr. B. Ameduri dealing with the synthesis of original fluorinated elastomers using controlled radical polymerization (e.g., iodine transfer polymerization). Since October 2006, he has been a senior research fellow under the direction of Prof. Thomas Davis in the Centre of Advanced Macromolecular Design (CAMD), University of New South Wales. His research interests mainly cover the preparation of well-defined polymers, protein-polymer conjugates, and hybrid organic-inorganic nanoparticles using controlled radical polymerization. He has coauthored over 40 peer-reviewed research papers, including 2 book chapters, and 2 patents. Volga Bulmus received her B.E. and M.Sc. in Chemical Engineering and her Ph.D. in bioengineering (Hacettepe University, Turkey), in 2000. She worked as a postdoctoral research fellow in the Bioengineering Department at the University of Washington between 2001 and 2003. In 2004, she was granted a highly competitive The University of New South Wales (UNSW) Vice Chancellor's Research Fellowship (Australia). In 2008, she was appointed as a Senior Lecturer at the School of Biotechnology and Biomolecular Sciences (UNSW). She is also an adjunct member of The Centre for Advanced Macromolecular Design (CAMD) at UNSW. Dr. Bulmus leads a group of 5-10 researchers working on the development of advanced polymers for biotechnology and biomedical applications. She has published over 45 peer reviewed research papers. Her research interests include design, synthesis, and evaluation of well-defined polymeric systems for nanobiotechnology and drug delivery applications ranging from antitumor chemotherapy and gene silencing to bioseparations and biosensors. Tom Davis has been an academic at UNSW for 17 years following a stint in industry as a research manager at ICI in the U.K. He has coauthored 315+ reviewed papers, patents, and book chapters. He is the Director of the Centre for Advanced Macromolecular Design (CAMD) at UNSWsa Centre with expertise in bio/organic polymer synthesis and polymerization kinetics. He is also a visiting Professor at the Institute for Materials Research & Engineering (IMRE) in Singapore. In 2005 he was awarded a Federation Fellowship by the Australian Research Council. He serves (or has served) on the editorial advisory boards of Macromolecules,

show abstract

Section: Soluble Polymer-drug Conjugatesmentioning

confidence: 99%

Bioapplications of RAFT Polymerization

et al. 2009

View full text Add to dashboard Cite

show abstract

“…lecular coordination. Infrared and nmr (22,23) as well as In addition to the compounds 14a (this work) and 18 FAB mass spectroscopic data (24) indicated a boronate cage which represent the first structurally characterized ~1 -structure featuring a tetracoordinated boron atom. …”

Section: Resultsmentioning

confidence: 58%

Structural studies of organoboron compounds. LVII. Synthesis and structure of bicyclic boron-nitrogen betaines. 1-Methyl-5-(3-nitrophenyl)-4,6,9-trioxa-1-azonia-5-boratabicyclo[3.3.1]nonane and 3,3,4-trimethyl-1-(3-nitrophenyl)-2,6,7-trioxa-3-azonia-1-boratabicyclo[2.2.2]octane

Ahlenstiel¹,

Kliegel²,

Rettig³

et al. 1993

Can. J. Chem.

View full text Add to dashboard Cite

The syntheses and structures of the bicyclic boron-nitrogen betaines l-methyl-5-(3-nitrophenyl)- 4,6, 7a, and 3,3, Introductionoxide 5 undergoing an intramolecular 0 + B coordination The condensation of bis(2-hydroxyethy1)amines 1 and arylboronic acids leads to 1,3-dioxa-6-aza-2-boracyclooctanes 2 that are known to undergo transannular N + B coordination to form the stable bicyclo[3.3.0]octane ring systems 3. The structure 3 for these materials has been confirmed by chemical and physical investigations ( I ) , including an X-ray crystallographic analysis of the N-unsubstituted derivative 3 (R = H, Ar = C6H,) (2). Employing the Noxides 4, obtained by reaction of 1 with hydrogen peroxide (3,4), the condensation with an arylboronic acid could result in both the eight-membered cyclic arylboronate 5 and the six-membered chelate 6.4 Both products (5 and 6) could subsequently cyclize to the bridged-ring compound 7 , the N-

show abstract

“…An important area for the potential application of pharmacologically active polymers is the development of macromolecules with carcinolytic activity [12, [33][34][35][36]. The field of polymeric antitumor agents has been reviewed recently [37].…”

Section: N H -C H~mentioning

confidence: 99%

“…Based on the experiments of Connors et al 191 as discussed above, attempts were made to use sulfonamide side chains in polymers as homing devices for tumor tissue [36,51,521 which shows a low pH-value after treatment with glucose. Figure 12 summarizes several polysulfonamides and their precipitation behavior in vitro.…”

Section: N H -C H~mentioning

confidence: 99%

Structure and properties of pharmacologically active polymers

Ringsdorf

1975

J. polym. sci., C Polym. symp.

Self Cite

1,011

548

View full text Add to dashboard Cite

SYNOPSISAlthough the concept of using pharmacologically active macromolecular compounds as drugs is still regarded with much skepticism for both theoretical and practical reasons, interest in this field has grown in recent years because of the opportunity to take advantage of the specific properties of polymeric materials. For low molecular weight drugs, changes in structure often lead to a loss of specific activity. On the other hand, the properties of macromolecular drugs depend on the structure of the polymer used and this can be varied over a wide range by the incorporation of comonomer units, by the application of polymer-analogous reactions, or by related structural changes. A new model is presented for pharmacologically active polymers which incorporates the possibility for continuous variation in ( a ) solubility and toxicity, ( b ) fixation and removal of active material, and (c) body distribution. Using the new model as a guide, examples of the synthesis and study of the biological activity of various macromolecular drugs are presented in order to emphasize the importance of this cooperative effort between polymer research and therapeutic problems. 135

show abstract

Pharmacologically active polymers, 6. Sulfadiazine and boron derivatives as potential carriers for polymers into cancer tissue

Abstract: Sonderforschungsbereich 41, Chemie und Physik der Makromolekiile Mainz/Darmstadt,

Cited by 30 publications

References 4 publications

Bioapplications of RAFT Polymerization

Bioapplications of RAFT Polymerization

Structural studies of organoboron compounds. LVII. Synthesis and structure of bicyclic boron-nitrogen betaines. 1-Methyl-5-(3-nitrophenyl)-4,6,9-trioxa-1-azonia-5-boratabicyclo[3.3.1]nonane and 3,3,4-trimethyl-1-(3-nitrophenyl)-2,6,7-trioxa-3-azonia-1-boratabicyclo[2.2.2]octane

Structure and properties of pharmacologically active polymers

Contact Info

Product

Resources

About